Recipe — Therapeutic Peptide Stability Modifications
P1 recipe — protocol catalog from 2014-schneider-de-novo-molecular-design-book §18.4 (Hiss & Schneider, pp. ~456–460). Standard α-L-peptides degrade in serum (intravenous) and gastrointestinal tract (oral) — half-life is the pharmacokinetic limiter. The book’s §18.4 catalogues four chemical-modification classes for protease-resistance + plasma-half-life improvement, with worked examples for each. Apply this after sequence design (e.g., ACO output, see Recipe — Ant Colony Optimization for Peptide Sequence Design) but before in vivo testing.
Caveat from §18.4: “there is no apparent general rule how to increase stability and at the same time maintain biological activity. A chemical modification that proved to be working for one peptide can have no or detrimental effects on another.” Apply experimentally — these are starting points, not guarantees.
The four modification classes
1. Backbone cyclization (§18.4.1)
Cyclize via N→C amide bond, disulfide bridge, or computationally-designed Gly/Ala linker.
Use when:
- Peptide N- and C-termini are in 3D proximity (≤15 Å distance is the practical bridging limit; α-conotoxin MII case used ~11 Å bridge).
- Bioactivity does not require free termini.
Worked example: α-conotoxin MII cyclized variants cMII-6 / cMII-7 (Schneider 2014 §18.4.1 [76, 77]):
| Property | Wild-type | cMII-6 / cMII-7 |
|---|---|---|
| Linker sequence | (none) | GGAAGG / GAGAAGG |
| Plasma stability | baseline | +15–20% improvement |
| EndoGluc protease resistance | baseline | ”significant” improvement (qualitative) |
| nicotinic AChR IC₅₀ | ~1 µM | ~1 µM (preserved) |
Linker design: Gly + Ala only (small side chains, do not interact with peptide core; Gly especially adopts wide backbone-torsion range — good for turn). Energy-minimize with structure-based modeling. PDB IDs: 1mii (WT), 2ajw (cMII-6), 2ak0 (cMII-7).
2. All-hydrocarbon stapling (§18.4.2)
Crosslink i, i+3 or i, i+4 or i, i+7 positions of an α-helix with an alkene-bridge from α-methyl, α-alkenylglycine residues. Verdine & Hilinski 2012.
Use when:
- Peptide is α-helical and needs membrane permeability (cell-penetrating).
- Targeting protein-protein interfaces (e.g., transcription factor binding).
Selection rule (Schneider 2014 §18.4.2 [79]): “the (i, i+3) cross-links turned out to lead to the least deformation of the helix axis.”
Naming: X_Y where X = stereochemistry at α-carbon, Y = alkenyl side-chain length.
3. End-capping (§18.4.3)
Modify N- and/or C-terminal amino acids to defeat exopeptidase recognition.
Use when:
- Linear peptide cannot be cyclized.
- Bioactivity does not require free amine/carboxylate termini.
Modifications:
- N-terminal acetylation
- C-terminal amidation
- N-terminal deamination
- Both ends capped (“Cap-MART-1” worked example)
- C-terminal PEGylation (PEG-MART-1)
- PASylation: fusion of Pro-Ala-Ser repeats (Skerra and coworkers [84]; alternative to PEGylation that’s biodegradable). Worked example: PAS-insulin → improved plasma half-life.
MART-1 worked example (Schneider 2014 §18.4.3 [80, 83]): N-Ac, C-NH₂, double-cap, and PEG all stabilized; D-aa substitutions and N-glycosylation did NOT stabilize MART-1.
4. Glycosylation / sugar-coating (§18.4.4)
Attach O- or N-linked GlcNAc (and longer sugar chains via enzymatic transglycosylation with EndoM).
Use when:
- Need increased thermal stability + aqueous solubility + bioavailability + protease resistance simultaneously.
- Want carbohydrate-mediated additional binding interactions (e.g., glycopeptide T → T-cell receptor).
Worked examples (Schneider 2014 §18.4.4):
- Peptide T (ASTTTNYT, HIV gp120 partial sequence): glycosylated form much more stable in human plasma than wild-type or N-acetylglucosaminyl-only [86].
- FAPSNYPAL → MHC-I H-2D^b crystal structure (PDB 1qlf): GlcNAc residue is solvent-exposed and adds T-cell-receptor interaction.
Synthesis route: Use modified GlcNAc-Asn during solid-phase synthesis → enzymatic transglycosylation with EndoM (or wild-type / mutant glycosidases) to elaborate carbohydrate chain.
Decision matrix for h09
| h09 use case | Recommended modification | Rationale |
|---|---|---|
| RADA16-like self-assembling peptide for in vivo cochlear injection | End-capping (N-Ac, C-NH₂) + optional PASylation | Termini-cap is minimal disruption to the β-sheet H-bond network |
| α-helical bundle peptide for OHC-membrane targeting | i, i+3 stapling | Preserves helix axis, adds protease resistance |
| Conotoxin-style disulfide-loop peptide for OHC ion channel | Backbone cyclization with Gly/Ala linker | Requires N-/C-terminus proximity; conotoxin precedent |
| WH2-bundling peptide for h09 phase 2c | Backbone cyclization if termini are buried; end-capping if exposed | Test both, gate on hydrogel rheology |
| Any in vivo formulation | At minimum end-capping; additionally PEGylation/PASylation | bioavailability + half-life |
How to integrate with ACO design (h09 workflow)
- Run ACO sequence-space exploration (Recipe — Ant Colony Optimization for Peptide Sequence Design) → top-K candidate sequences ranked by self-assembly fitness.
- For each top-K candidate, generate two stability variants: (a) Ac-N + C-NH₂ end-capped, (b) backbone-cyclized via Gly₃-linker if termini are ≤15 Å apart in predicted structure.
- Validate self-assembly is preserved (CD spectroscopy: keep β-sheet signature ≈ 218 nm minimum; keep T-melt ≥ 50°C).
- If self-assembly is preserved, advance to in vivo PK testing.
- If self-assembly is broken by stability mod, fall back to wild-type and use external delivery vehicle (LNP, biodegradable hydrogel matrix) for protection.
Citation pattern for h09 in vivo prep docstring
# Therapeutic-peptide stability modifications per Schneider 2014 §18.4 (Hiss & Schneider).
# End-capping (N-acetylation + C-amidation): §18.4.3 [80].
# Backbone cyclization with Gly-Ala linker: §18.4.1 [76]; α-conotoxin MII precedent
# (15-20% plasma stability gain, IC50 preserved at ~1 µM nicotinic AChR).
# PASylation (Pro-Ala-Ser fusion as PEG alternative): §18.4.3 [84] (Skerra and coworkers).
Connections
[part-of]rada16-geometry[source]2014-schneider-de-novo-molecular-design-book[applies]index[see-also]Recipe — Ant Colony Optimization for Peptide Sequence Design[see-also]Amino Acid Physicochemical Distance Matrix Grantham Modified